Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 26, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.
Journal: Frontiers in oncology
Published: November 18, 2025
A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule-1 Biomarker.
Journal: Journal of pharmacology & clinical toxicology
Published: December 27, 2024
Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma.
Journal: Cancers
Published: September 04, 2024
Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT3 Antagonist Antiemetic Drugs.
Journal: Journal of clinical pharmacology
Published: June 28, 2024
Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 13, 2024
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.
Journal: Cancer discovery
Published: January 18, 2024
Publisher Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC.
Journal: Nature cancer
Published: January 10, 2024
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Journal: Thyroid : official journal of the American Thyroid Association
Published: December 08, 2023
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 04, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.
Journal: Future oncology (London, England)
Published: November 02, 2023
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 10, 2023
Last Updated: 09/26/2026